Does Adjuvant Radiotherapy Benefit Patients With Diffuse-Type Gastric Cancer? Results From the Surveillance, Epidemiology, and End Results Database

Publication Date

2014

Journal Title

Cancer

Abstract

BACKGROUND Diffuse-type gastric cancer is observed in approximately one-third of gastric cancers, yet the optimal treatment remains controversial. In the recently published Intergroup 0116 trial, a subgroup analysis demonstrated a lack of a long-term survival benefit for adjuvant chemoradiation therapy among patients with diffuse-type gastric cancer. METHODS The Surveillance, Epidemiology, and End Results registry database was queried for patients who were newly diagnosed with diffuse-type gastric cancer between 2002 and 2005 and underwent surgical resection with or without adjuvant radiotherapy (RT). Overall survival (OS) was analyzed by the Kaplan-Meier method. Cox proportional hazards models were used to investigate the association between adjuvant RT and OS, with and without adjusting for other factors. In addition, propensity score methods were used to control for the possible effects of measured confounders. RESULTS A total of 1889 cases of surgically resected diffuse-type gastric cancer were included in the analysis; of these cases, 782 patients received adjuvant RT and 1107 did not receive RT. The median survival time was 30 months in the group treated with adjuvant RT versus 18 months in the group that did not receive RT with matched propensity scores (P

Volume Number

120

Issue Number

22

Pages

3562-3568

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Molecular Medicine

PMID

25043858

DOI

10.1002/cncr.28913

For the public and Northwell Health campuses

Share

COinS